Nouvelles hormonothérapies dans le cancer de la prostate

In recent years, the best understanding of castration resistance mechanisms developed by prostate cancer cells led to the emergence of new hormone therapies. A first GnRH antagonist, degarelix, was approved for clinical use in advanced prostate cancer. More recently, abiraterone, an inhibitor of cytochrome CYP17, showed an increase in overall survival in patients with metastatic castration-resistant prostate cancer progressing after docétaxel use. In chemotherapy-naïve patients, abiraterone showed an increase in radiologic progression free survival in early results. Finally enzalutamide (MDV3100), a new nonsteroidal androgen androgen receptor antagonist, has also led to a survival benefit for metastatic patients previously treated with docetaxel. These new drugs evaluation is in progress in randomized trials at earlier stages disease. Moreover other molecules of the same pharmacotherapeutic group are in development.